Clinical Response and Safety of Alternating Daily Dosage of Crizotinib due to Side Effects in Advanced NSCLC patient harboring ROS1-rearrangement: A Case Report. J Respirol Indones. 2023;43(2):111-115. doi:10.36497/jri.v43i2.201